Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada

被引:0
|
作者
DeWals, P
Dionne, M
DouvilleFradet, M
Boulianne, N
Drapeau, J
DeSerres, G
机构
[1] DIRECT SANTE PUBL MONTEREGIE,ST HUBERT,PQ,CANADA
[2] CTR SANTE PUBL QUEBEC,BEAUPORT,PQ,CANADA
[3] CHU SHERBROOKE,CLIN RES CTR,SHERBROOKE,PQ J1H 5N4,CANADA
关键词
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
A mass immunization campaign was conducted in the Province of Quebec, Canada, during the winter of 1993, following an increase in the incidence of meningococcal disease, which was mainly caused by a virulent clone of Neisseria meningitidis, serogroup C, serotype 2a. About 1.6 million doses of the polysaccharide vaccine were administered, covering 84% of the target population aged between 6 months and 20 years; the overall cost was about 25.5 million Canadian dollars. Cases notified to the regional health authorities by clinicians, hospital laboratories, and the provincial reference laboratory from January 1990 up to March 1994 have been included in the analysis. In the first year following the campaign, the incidence of the disease dropped markedly among vaccinees as well as the unvaccinated fraction of the target population, while it remained unchanged among persons aged more than 20 years. This suggests the existence of herd immunity. The overall field efficacy of the vaccine was 79%, more in teenagers and less in under-5-year-olds. A minimum of 37 cases were prevented during the first year.
引用
收藏
页码:407 / 411
页数:5
相关论文
共 50 条
  • [1] Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec
    De Wals, P
    De Serres, G
    Niyonsenga, T
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (02): : 177 - 181
  • [2] Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec
    De Wals, P
    Erickson, L
    [J]. VACCINE, 2002, 20 (21-22) : 2840 - 2844
  • [3] Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada
    De Wals, Philippe
    Deceuninck, Genevieve
    Lefebvre, Brigitte
    Tsang, Raymond
    Law, Dennis
    De Serres, Gaston
    Gilca, Vladimir
    Gilca, Rodica
    Boulianne, Nicole
    [J]. CLINICAL INFECTIOUS DISEASES, 2017, 64 (09) : 1263 - 1267
  • [4] Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine
    De Wals, P
    Deceuninck, G
    Boulianne, N
    De Serres, G
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (20): : 2491 - 2494
  • [5] Analysis of mortality following a mass immunization campaign with serogroup C meningococcal conjugate vaccine
    De Wals, Philippe
    [J]. VACCINE, 2009, 27 (42) : 5730 - 5730
  • [6] Serogroup c meningococcal immunization campaign in the United Kingdom
    Kaczmarski, E
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2002, 63 : A30 - A37
  • [7] Rationale of recommendations for universal immunization against meningococcus C in France
    Grimprel, E.
    [J]. ANTIBIOTIQUES, 2010, 12 (04): : 249 - 253
  • [9] Impact of a mass immunization campaign to control an outbreak of severe respiratory infections in Nunavik, northern Canada
    Ndiaye, Abdoul Aziz
    De Wals, Philippe
    Proulx, Jeon-Francois
    Ouakki, Manale
    Jette, Louise
    Dery, Serge
    [J]. INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH, 2006, 65 (04) : 297 - 304
  • [10] Analysis of mortality following a mass immunization campaign with serogroup C meningococcal conjugate vaccine: Methodological difficulties and imperfect solutions
    De Wals, Philippe
    Deceuninck, Genevieve
    Ouakki, Manale
    Boulianne, Nicole
    De Serres, Gaston
    Danzig, Lisa
    [J]. VACCINE, 2009, 27 (24) : 3223 - 3227